Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease - 11/06/26

Doi : 10.1016/j.tjpad.2026.100619 
Xu Xu a, b, 1, Lintong Li c, d, 1, Wei Huang a, b, Ying Yang e, Xu Li f, Pei Wang g, Mengmeng Zhao h, Huiliang Zhang i, 2, ⁎ , Chaoming Yuan a, b, 2, ⁎
a Department of Neurology, The Third People's Hospital of Yunnan Province, China 
b Department of Neurology, The Second Affiliated Hospital of Dali University, China 
c Department of Endocrinology, The Third People's Hospital of Yunnan Province, China 
d Department of Endocrinology, The Second Affiliated Hospital of Dali University, China 
e Department of Neurology, Yiliu Subdistrict Community Health Service Center of Guandu District, Kunming City, China 
f Department of Neurology, Shalatuo Township Health Center, Yuanyang City, China 
g Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 
h Department of Neurology, Zhengzhou Emergency Medical Rescue Center, Zhengzhou, China 
i Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan 430000, China 

⁎ Corresponding author at: The Second Affiliated Hospital of Dali University, Dali 671000, China. The Second Affiliated Hospital of Dali University Dali 671000 ∗∗ Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

Changes in neuroimaging metrics are among the first detectable pathophysiological alterations in Alzheimer's disease (AD). Proteins are closely linked to fluctuations in neuroimaging metrics. Therefore, the analysis of the proteomic signature associated with neuroimaging metrics holds significant promise for uncovering therapeutic targets that contribute to AD.

Methods

GWAS data concerning the Brain Imaging Data Structure (BIDs). The AD cohort comprised a total of 401,661 individuals diagnosed with AD, alongside 10,520 control participants. For a bidirectional MR analysis involving neuroimaging metrics, proteomics, and AD, the methods utilized included inverse variance weighted (IVW), MR Egger, weighted median, weighted mode, and the Wald ratio approaches.

Results

We identified 12 neuroimaging metrics that demonstrate significant relevance to AD (thickness of the left total hemisphere, volume of the right thalamus, and et al.). These metrics are structural magnetic resonance imaging (MRI) biomarkers that remain stable throughout the entire course of AD, from the preclinical stage through mild cognitive impairment (MCI) to dementia. Additionally, we found a substantial number of 1633 proteins that also show a noteworthy causal relationship with AD. Functional enrichment analysis indicated that these proteins were predominantly focused within various pathways linked to AD, encompassing those involved in the synaptic vesicle cycle, synaptic membranes, neurotransmitter release, and the activity of GABA receptors. In addition, our research indicates that the significant relationships observed between the identified proteins and AD are influenced by neuroimaging metrics. Notably, we found that these neuroimaging metrics play a crucial role in mediating a substantial 67% of the inverse relationship that exists between PTPRC and the phenotypic characteristics associated with AD.

Conclusions

This study successfully establishes a connection between proteomic and neuroimaging metrics, as well as the AD that influence them. By creating this relationship, the research offers important information that aids in comprehending the intricate mechanisms involved in AD.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Alzheimer's disease, Neuroimaging metrics, Proteomic, Mendelian randomization


Mappa


© 2026  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 13 - N° 8

Articolo 100619- ottobre 2026 Ritorno al numero
Articolo precedente Articolo precedente
  • Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment
  • Elizabeth Kuhn, Luca Kleineidam, Melina Stark, Oliver Peters, Julian Hellmann-Regen, Lukas Preis, Daria Gref, Josef Priller, Eike Jakob Spruth, Maria Gemenetzi, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Claudia Bartels, Niels Hansen, Ayda Rostamzadeh, Emrah Düzel, Wenzel Glanz, Enise Incesoy, Katharina Buerger, Daniel Janowitz, Sophia Stöcklein, Robert Perneczky, Boris-Stephan Rauchmann, Stefan J. Teipel, Ingo Kilimann, Christoph Laske, Sebastian Sodenkamp, Annika Spottke, Marie Kronmüller, Sandra Roeske, Frederic Brosseron, Alfredo Ramirez, Matthis Synofzik, Matthias C. Schmid, Frank Jessen, Michael Wagner, Alzheimer’s Disease Neuroimaging Initiative, DELCODE study group
| Articolo seguente Articolo seguente
  • The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status
  • Marta Milà-Alomà, Isabella Hausle, Kellen K. Petersen, Pamela Thropp, Suzanne E. Schindler, Duygu Tosun, Alzheimer’s Disease Neuroimaging Initiative

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.